675 McDonnell Boulevard
About Mallinckrodt PharmaceuticalsMallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs.
Founder: Emil Mallinckrodt
CEO: Mark Trudeau
CFO: Matthew Harbaugh
Please click here for Mallinckrodt job opportunities.
282 articles with Mallinckrodt Pharmaceuticals
Mallinckrodt Files Suit against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) to Protect Medicaid Patient Access to Acthar® Gel
Mallinckrodt plc confirmed its subsidiary, Mallinckrodt ARD LLC, has filed suit in federal district court against the HHS and CMS.
Mallinckrodt's CONFIRM study is evaluating the efficacy and safety of terlipressin in hepatorenal syndrome type 1
Mallinckrodt plc Reports Strong Growth in First Quarter 2019 Results, Raises Guidance for 2019, and Continues to Make Significant Advancements in Pipeline and Data Generation
Net sales up 4.7%, or 5.0% on a constant-currency basis, on $790.6 million, led by strong performance of hospital products and the Specialty Generics and Amitiza segment
Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt Announce Results from Pivotal Phase 3 Trial of CPP-1X/Sulindac in Patients with Familial Adenomatous Polyposis
Full data to be presented in detail by CPP at Digestive Disease Week (DDW) conference on May 19, 2019 at 5:19 pm Pacific Time
Mallinckrodt Announces Encouraging Interim Analysis Results in Phase 4 Registry of INOmax® (Nitric Oxide) Gas for Inhalation for Pulmonary Hypertension in Neonates
Observational registry (at midway point) with retrospective data collection provides preliminary evaluation of premature versus term and near-term neonates with pulmonary hypertension receiving inhaled nitric oxide
Mallinckrodt Lupus Phase 4 Clinical Study for Acthar® Gel (Repository Corticotropin Injection) Completes Enrollment in Difficult-to-Manage Population
Company continues focus on evidence expansion, potential utility of Acthar Gel in appropriate, underserved patients
Mallinckrodt Reports Top-Line Results from Proof-of-Concept Study of Nitric Oxide Gas in Ex-Vivo System of Human Lung Transplants
Study showed oxygenation improvement and increased out-of-body perfusion duration
Data on Impact of Revised Consensus Recommendations on Time to Treatment and Serum Creatinine (SCr) at Treatment Start for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Presented at the 2019 International Liver Congress™ (EASL)
Retrospective analysis showed applying latest International Club of Ascites (ICA) diagnostic criteria would be estimated to result in earlier time to treatment at a lower SCr level and potentially improved outcomes
Mallinckrodt Completes Full Enrollment of its Phase 3 Clinical Trial for StrataGraft® Regenerative Skin Tissue
Pivotal Phase 3 study is evaluating efficacy and safety of investigational regenerative skin tissue in adults with deep partial-thickness burns
Discovery program aimed at identifying potential new drugs targeting chronic itch, a serious condition spanning multiple disorders
Data Published on Acthar® Gel (repository corticotropin injection) Disease Status and Utilization Patterns in Uveitis Patients in Journal of Ocular Pharmacology and Therapeutics
Retrospective chart review also reports on use of concomitant uveitis medication during and after treatment with Acthar Gel
Mallinckrodt Achieves Top Score in 2019 Corporate Equality Index for Third Year in a Row, Recognized as a Best Place to Work for LGBTQ Equality
Company earns 100 percent on Human Rights Campaign Foundation's 17th annual scorecard on LGBTQ Workplace Equality
Mallinckrodt plc, a leading global specialty pharmaceutical company, announced that it will report first quarter 2019 earnings results for the period ending March 29, 2019, on Tuesday, May 7, 2019.
St. Louis, Missouri is one of the fastest-growing and top-ranked emerging life sciences markets in the U.S., ranking sixth in a recent CBRE Research report.
Brings substantial CFO, finance expertise and pharmaceutical industry experience
Mallinckrodt's Hobart, N.Y. and St. Louis, Mo. Sites Recognized as 2019 Manufacturing Leadership Award Winners
Hobart site honored for second year in a row, recognized this year for talent management leadership
Mallinckrodt Presents New Data on Real-World Resource Utilization Associated with Continuation of Systemic Treatment among Patients with Cutaneous T-cell Lymphoma at 2019 American Academy of Dermatology Annual Meeting
Retrospective study analyzed the relationship between continued systemic treatment and various healthcare resources and costs such as ER costs, ER visits, hospitalizations, and total inpatient days
Mallinckrodt plc Reports Strong Fourth Quarter and Total Company 2018 Results, Announces 2019 Guidance and Strategic Priorities
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, reported results for the three months and fiscal year ended Dec. 28, 2018.
Mallinckrodt Announces Extracorporeal Photopheresis Research Collaboration Agreement With Transimmune AG
Collaboration with experts in photopheresis field expected to further enhance understanding of photopheresis' effect on immune modulation across a range of severe and critical conditions
Mallinckrodt Announces Interim Analysis Results for Therakos® Platform Phase 3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute Graft-versus-Host Disease
Overall response rate exceeded specified study midpoint target (n=25); company elects to discontinue further patient enrollment as allowed by protocol